Home › Pfizer's RAPAMUNE (sirolimus) Becomes First FDA-Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease
 

Keywords :   


Pfizer's RAPAMUNE (sirolimus) Becomes First FDA-Approved Treatment For Lymphangioleiomyomatosis (LAM), A Rare Progressive Lung Disease

2015-06-03 06:19:12| drugdiscoveryonline Home Page

Pfizer Inc. announced recently that the U.S. Food and Drug Administration (FDA) has approved RAPAMUNE (sirolimus) for the treatment of lymphangioleiomyomatosis (LAM), a rare, progressive disease that affects the lungs, kidneys and the lymphatic system

Tags: treatment disease rare progressive

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
23.11PlayStationVitaPCH-2000
23.11GB
23.11 Malbon
23.11PING PEARL GATES
23.11WATCH
23.11L
23.11Tetsuya_SP2 DMC
23.116
More »